Skip to main content

Advertisement

SpringerLink
Log in

Fulvestrant and male breast cancer: a pooled analysis

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Male breast cancer is an uncommon malignancy; little is known regarding hormonal manipulations for tamoxifen-resistant male breast cancer patients. This is the first pooled analysis of the literature to synthesize all available data and to evaluate the efficacy and safety of fulvestrant in male breast cancer. This study was performed in accordance with the PRISMA guidelines. All studies that examined the efficacy of fulvestrant in male breast cancer, regardless of sample size, were considered eligible. The search strategy retrieved 31 articles; of these, five articles were eligible (23 patients) for this pooled analysis. The mean age of the study sample was 63.1 years. Adjuvant hormonal treatment was administered in 87.5 % of cases. Fulvestrant was given as first or second line in 40 % of patients, while as third line or beyond in 60 % of patients. 79.0 % of patients at fulvestrant administration had visceral metastases. Regarding best response, in 26.1 % PR was achieved, in 47.8 % of cases SD was recorded, whereas in 26.1 % of patients PD was noted. The median PFS was equal to 5 months. No grade 3 and 4 adverse events were recorded; of note, hot flashes were reported in 18.2 % of male breast cancer patients. Fulvestrant may potentially play a promising role in the optimal therapeutic strategy for male patients with breast cancer diagnosis. However, further clinical and pharmacokinetic investigations are more than warranted before fulvestrant use becomes a common practice in male breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, Schatzkin A (2008) Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 100:1477–1481

    Article  PubMed Central  PubMed  Google Scholar 

  2. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3 (2014). Available at www.nccn.com

  3. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871–1888

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23:489–502

    Article  CAS  PubMed  Google Scholar 

  5. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M (2002) Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81:333–341

    Article  CAS  PubMed  Google Scholar 

  6. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M (2014) Final overall survival: fulvestrant 500 mg versus 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106(1):djt337

    Article  PubMed Central  PubMed  Google Scholar 

  7. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664–1670

    Article  CAS  PubMed  Google Scholar 

  8. Liberati A, Altman DG, Tetzlaff J (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34

    Article  PubMed  Google Scholar 

  9. Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G, Zografos G, Bartsch R (2013) Fulvestrant and male breast cancer: a case series. Ann Oncol 24:265–266

    Article  CAS  PubMed  Google Scholar 

  10. Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R (2011) A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat 129:819–827

    Article  CAS  PubMed  Google Scholar 

  11. Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA (2011) Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 17:4799–4805

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, De Greve J, Fontaine C, Van Den Weyngaert D, Becquart D, Borms M, Cocquyt V, Van Den Broecke R, Selleslags J, Awada A, Dirix L, Van Dam P, Azerad MA, Vandenhoven G, Christiaens MR, Vergote I (2008) Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 109:59–65

    Article  PubMed  Google Scholar 

  13. Masci G, Gandini C, Zuradelli M, Pedrazzoli P, Torrisi R, Lutman FR, Santoro A (2011) Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol 22:985

    Article  CAS  PubMed  Google Scholar 

  14. de la Haba Rodríguez JR, Quintela IP, Cortijo GP, Guerrero MB, Aranda E (2009) Fulvestrant in advanced male breast cancer. Ann Oncol 20:1896–1897

    Article  PubMed  Google Scholar 

  15. Agrawal A, Cheung KL, Robertson JF (2007) Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 101:123

    Article  PubMed  Google Scholar 

  16. Carmona-Bayonas A (2007) Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer. Breast 16:323–325

    Article  CAS  PubMed  Google Scholar 

  17. Onami S, Ozaki M, Mortimer JE, Pal SK (2010) Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas 65:308–314

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH (1998) Molecular markers in male breast carcinoma. Cancer 83:1947–1955

    Article  CAS  PubMed  Google Scholar 

  19. Stalsberg H, Thomas DB, Rosenblatt KA, Jimenez LM, McTiernan A, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF et al (1993) Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control 4:143–151

    Article  CAS  PubMed  Google Scholar 

  20. Farrow JH, Adair FE (1942) Effect of orchidectomy on skeletal metastases from cancer of the male breast. Science 95:654

    Article  CAS  PubMed  Google Scholar 

  21. White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V (2011) Male breast carcinoma: increased awareness needed. Breast Cancer Res 13:219

    Article  PubMed Central  PubMed  Google Scholar 

  22. Arriola E, Hui E, Dowsett M, Smith IE (2007) Aromatase inhibitors and male breast cancer. Clin Transl Oncol 9:192–194

    Article  CAS  PubMed  Google Scholar 

  23. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN (2002) Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25:235–237

    Article  PubMed  Google Scholar 

  24. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G (1983) Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143:237–240

    Article  CAS  PubMed  Google Scholar 

  25. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos MA, Bartsch R (2013) Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108:2259–2263

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Giordano SH, Hortobagyi GN (2006) Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24:e42–e43

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Clinical Therapeutics, Medical School, Alexandra Hospital, University of Athens, Vas Sofias Ave & Lourou str, 11521, Athens, Greece

    Flora Zagouri, Dimosthenis Chrysikos & Meletios-Athanasios Dimopoulos

  2. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece

    Theodoros N. Sergentanis & Theodora Psaltopoulou

Authors
  1. Flora Zagouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theodoros N. Sergentanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimosthenis Chrysikos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meletios-Athanasios Dimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Theodora Psaltopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Flora Zagouri.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zagouri, F., Sergentanis, T.N., Chrysikos, D. et al. Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat 149, 269–275 (2015). https://doi.org/10.1007/s10549-014-3240-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-3240-z

Keywords

Search

Navigation